JP2025533366A - ＩＦＮβ抗体を用いた処置の方法 - Google Patents

ＩＦＮβ抗体を用いた処置の方法

Info

Publication number
JP2025533366A
JP2025533366A JP2024506143A JP2024506143A JP2025533366A JP 2025533366 A JP2025533366 A JP 2025533366A JP 2024506143 A JP2024506143 A JP 2024506143A JP 2024506143 A JP2024506143 A JP 2024506143A JP 2025533366 A JP2025533366 A JP 2025533366A
Authority
JP
Japan
Prior art keywords
weeks
antibody
ifnβ
patient
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024506143A
Other languages
English (en)
Japanese (ja)
Inventor
サンジェイ アレカー シルパ
バナジー アニンディタ
リカルド バンフィールド クリストファー
サックゾー ビービ ジーン
エドワード チュー マイロン
リー ハイド クレイグ
リー ジョンソン クリステン
ジョセフ リジ
リー シンペン
ニーラカンタン スリヴィドヤ
セティアワン オマール バリー
ピーヴァ エレーナ
ナタリー ラス ジーン
ピーター セルガニク ミカイル
グレース スローン アビゲイル
ティワリ アブヒナブ
アン ウェブ チャンドラ
ジーメック ダニエル
Original Assignee
ファイザー・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・インク filed Critical ファイザー・インク
Publication of JP2025533366A publication Critical patent/JP2025533366A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2024506143A 2022-09-22 2023-09-21 ＩＦＮβ抗体を用いた処置の方法 Pending JP2025533366A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263376722P 2022-09-22 2022-09-22
US63/376,722 2022-09-22
US202363490120P 2023-03-14 2023-03-14
US63/490,120 2023-03-14
US202363583336P 2023-09-18 2023-09-18
US63/583,336 2023-09-18
PCT/IB2023/059364 WO2024062420A1 (fr) 2022-09-22 2023-09-21 Procédés de traitement avec des anticorps ifnss

Publications (1)

Publication Number Publication Date
JP2025533366A true JP2025533366A (ja) 2025-10-07

Family

ID=88236876

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024506143A Pending JP2025533366A (ja) 2022-09-22 2023-09-21 ＩＦＮβ抗体を用いた処置の方法

Country Status (4)

Country Link
EP (1) EP4590699A1 (fr)
JP (1) JP2025533366A (fr)
TW (1) TW202426493A (fr)
WO (1) WO2024062420A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026015672A1 (fr) * 2024-07-09 2026-01-15 RESTEM Group, Inc. Cellules souches dérivées de revêtement ombilical pour le traitement de la myopathie inflammatoire idiopathique

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
WO1993010260A1 (fr) 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Utilisation de la neuraminidase extracellulaire pour lutter contre la degradation d'oligosaccharides de la glycoproteine
CA2604238C (fr) 2005-04-15 2015-07-07 Neogenix Oncology, Inc. Anticorps monoclonaux recombines et antigenes correspondants contre les cancers du colon et du pancreas
CA2965652A1 (fr) * 2016-04-29 2017-10-29 Pfizer Inc. Anticorps d'interferon beta

Also Published As

Publication number Publication date
EP4590699A1 (fr) 2025-07-30
WO2024062420A1 (fr) 2024-03-28
TW202426493A (zh) 2024-07-01

Similar Documents

Publication Publication Date Title
JP7654346B2 (ja) 多重特異性抗体およびその使用
TW202024131A (zh) 抗-αvβ8抗體及組合物及其用途
JP2022512722A (ja) 抗ｃｄ３８抗体の皮下投与を提供する方法
KR20250009424A (ko) 항-tl1a 항체 및 그의 사용 방법
JP2025533366A (ja) ＩＦＮβ抗体を用いた処置の方法
JP7668943B2 (ja) 多重特異性抗体およびその使用
CA3048198A1 (en) Methods of treating multiple myeloma
KR20250034263A (ko) 다중특이적 항체 및 그의 용도
JP2025036273A (ja) 多重特異性抗体およびその使用
KR20250034106A (ko) 항-il27r 항체 및 그의 사용 방법
KR20250067723A (ko) 항-tl1a 항체 및 그의 사용 방법
AU2023279258A1 (en) Anti-bmp9 antibodies and methods of use thereof
JP2025124594A (ja) 抗ｉｌ２７ｒ抗体およびその使用の方法
KR20250119448A (ko) 항-il27r 항체 및 그의 사용 방법
HK40119918A (zh) 多特异性抗体及其用途
TW202535909A (zh) 補體相關腎病之治療
HK40119132A (zh) 与il-4、il-13和/或tslp结合的多特异性抗体及其用途
HK40118644A (zh) 抗-tl1a抗体及其使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240229